News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
769,477 Results
Type
Article (57328)
Company Profile (350)
Press Release (711799)
Multimedia
Podcasts (103)
Webinars (14)
Section
Business (220393)
Career Advice (2989)
Deals (37971)
Drug Delivery (124)
Drug Development (87544)
Employer Resources (187)
FDA (17422)
Job Trends (16352)
News (374520)
Policy (36525)
Tag
Academia (2955)
Academic (1)
Accelerated approval (5)
Adcomms (29)
Allergies (94)
Alliances (53964)
ALS (99)
Alzheimer's disease (1496)
Antibody-drug conjugate (ADC) (154)
Approvals (17391)
Artificial intelligence (294)
Autoimmune disease (28)
Automation (16)
Bankruptcy (391)
Best Places to Work (12381)
BIOSECURE Act (20)
Biosimilars (119)
Biotechnology (235)
Bladder cancer (85)
Brain cancer (31)
Breast cancer (298)
Cancer (2416)
Cardiovascular disease (202)
Career advice (2517)
Career pathing (34)
CAR-T (172)
Cell therapy (469)
Cervical cancer (21)
Clinical research (70890)
Collaboration (899)
Compensation (542)
Complete response letters (28)
COVID-19 (2847)
CRISPR (48)
C-suite (262)
Cystic fibrosis (106)
Data (2263)
Decentralized trials (2)
Denatured (31)
Depression (55)
Diabetes (293)
Diagnostics (6779)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (131)
Drug pricing (123)
Drug shortages (32)
Duchenne muscular dystrophy (101)
Earnings (90827)
Editorial (44)
Employer branding (23)
Employer resources (160)
Events (122144)
Executive appointments (770)
FDA (18735)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (793)
Gene editing (118)
Generative AI (26)
Gene therapy (345)
GLP-1 (839)
Government (4957)
Grass and pollen (6)
Guidances (67)
Healthcare (20423)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (144)
Indications (30)
Infectious disease (3006)
Inflammatory bowel disease (153)
Inflation Reduction Act (9)
Influenza (54)
Intellectual property (101)
Interviews (575)
IPO (17270)
IRA (49)
Job creations (4407)
Job search strategy (2070)
Kidney cancer (11)
Labor market (38)
Layoffs (541)
Leadership (24)
Legal (9096)
Liver cancer (81)
Lung cancer (344)
Lymphoma (159)
Machine learning (7)
Management (64)
Manufacturing (338)
MASH (75)
Medical device (14217)
Medtech (14222)
Mergers & acquisitions (21244)
Metabolic disorders (776)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (113)
Neuropsychiatric disorders (34)
Neuroscience (2099)
NextGen: Class of 2025 (7278)
Non-profit (4968)
Now hiring (39)
Obesity (420)
Opinion (266)
Ovarian cancer (78)
Pain (98)
Pancreatic cancer (86)
Parkinson's disease (160)
Partnered (21)
Patents (247)
Patient recruitment (116)
Peanut (51)
People (62992)
Pharmaceutical (96)
Pharmacy benefit managers (20)
Phase I (21977)
Phase II (31010)
Phase III (23326)
Pipeline (1252)
Policy (165)
Postmarket research (3039)
Preclinical (9466)
Press Release (71)
Prostate cancer (112)
Psychedelics (38)
Radiopharmaceuticals (266)
Rare diseases (426)
Real estate (6671)
Recruiting (73)
Regulatory (24764)
Reports (47)
Research institute (2611)
Resumes & cover letters (470)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (140)
Series B (91)
Service/supplier (14)
Sickle cell disease (58)
Special edition (17)
Spinal muscular atrophy (162)
Sponsored (32)
Startups (3979)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (46)
The Weekly (70)
Vaccines (804)
Venture capitalists (43)
Weight loss (296)
Women's health (36)
Worklife (20)
Date
Today (207)
Last 7 days (935)
Last 30 days (2786)
Last 365 days (34593)
2025 (11350)
2024 (37170)
2023 (42114)
2022 (53388)
2021 (58132)
2020 (57015)
2019 (50414)
2018 (38267)
2017 (35229)
2016 (35339)
2015 (41366)
2014 (35408)
2013 (30879)
2012 (32873)
2011 (33445)
2010 (31531)
Location
Africa (969)
Alabama (59)
Alaska (7)
Arizona (249)
Arkansas (14)
Asia (44755)
Australia (7853)
California (6305)
Canada (2046)
China (558)
Colorado (274)
Connecticut (290)
Delaware (156)
Europe (98906)
Florida (926)
Georgia (213)
Idaho (61)
Illinois (590)
India (29)
Indiana (325)
Iowa (11)
Japan (167)
Kansas (107)
Kentucky (26)
Louisiana (11)
Maine (62)
Maryland (948)
Massachusetts (4801)
Michigan (227)
Minnesota (409)
Mississippi (2)
Missouri (89)
Montana (30)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1777)
New Mexico (31)
New York (1793)
North Carolina (1072)
North Dakota (9)
Northern California (2735)
Ohio (209)
Oklahoma (14)
Oregon (40)
Pennsylvania (1408)
Puerto Rico (13)
Rhode Island (35)
South America (1356)
South Carolina (23)
South Dakota (1)
Southern California (2359)
Tennessee (104)
Texas (934)
United States (24084)
Utah (189)
Virginia (159)
Washington D.C. (67)
Washington State (579)
West Virginia (3)
Wisconsin (57)
769,477 Results for "aveo oncology also known as aveo pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AVEO Oncology, an LG Chem company, Announces Three Poster Presentations at ASCO 2025 Annual Meeting
April 29, 2025
·
3 min read
Press Releases
AVEO Oncology, an LG Chem company, Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting
February 19, 2025
·
9 min read
Business
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
March 25, 2024
·
5 min read
Kidney Cancer
AVEO’s Fotivda Combo Flunks Phase III Renal Cell Carcinoma Study
While its investigational regimen fell short of the primary efficacy endpoint, AVEO dug into data from its control group and touted a “clinically meaningful” improvement in progression-free survival in patients receiving Fotivda monotherapy.
July 19, 2024
·
2 min read
·
Tristan Manalac
Drug Development
LG Chem company and AVEO Oncology Announce LG Chem’s First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.
LG Chem and AVEO Oncology, an LG Chem company, announced that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109, LG Chem’s first proprietary anti-cancer investigational drug candidate.
June 13, 2024
·
4 min read
Genetown
AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe’s 2023 Top Places to Work List for Second Consecutive Year
For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe’s annual ‘Top Places to Work in Massachusetts’ list.
November 30, 2023
·
3 min read
Press Releases
AVEO Oncology, an LG Chem company, Present TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024
September 16, 2024
·
9 min read
Press Releases
AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024
September 4, 2024
·
7 min read
Press Releases
AVEO Oncology, an LG Chem company, Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results
July 18, 2024
·
9 min read
Drug Development
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma
AVEO Oncology, an LG Chem company, (“AVEO”), announced today that it has completed enrollment in the pivotal Phase 3 TiNivo-2 study in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure.
June 27, 2023
·
7 min read
1 of 76,948
Next
